Odyssey Thera Granted U.S. Patent for GPCR Assay Strategy
News Feb 16, 2009
Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-Coupled Receptors and their Signaling Pathways."
The patent broadly covers methods for screening compounds and for identifying drug leads based on their ability to activate, inhibit or otherwise modulate G-protein-coupled receptors and the diverse signaling pathways linked to these receptors.
"This patent further extends and strengthens our deep patent estate in drug discovery and development technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "GPCRs are among the most valued targets for drug discovery, and our proprietary technologies enable GPCR-directed drug discovery in a native biological context. The fluorescence-based assays described in this patent are the only available strategy for capturing GPCR activities, including responses of hetero-dimeric GPCR complexes and diverse downstream effector proteins, in living human cells. These powerful new tools are essential in our search for more effective therapies for cancer and other un-met medical needs."
This is the thirteenth patent issued to Odyssey Thera, and solidifies its leadership position in cellular assay and drug discovery technologies. The inventions covered by this patent (U.S. Patent No. 7,488,583) were made by Odyssey Thera scientists.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018